Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC20 | Q5W0Z9 | 4/20 | 0.46 |
| ▸ | ZDHHC2 | Q9UIJ5 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 5/20 | 0.34 |
| ▸ | THRB | P10828 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2423529 | 0.86 | ZDHHC20 (0.37) | ZDHHC20ZDHHC2CA12CA1CA9 | |
| SCHEMBL2422782 | 0.80 | CA12 (0.41) | ZDHHC20ZDHHC2CA12CA1CA9 | |
| SCHEMBL15216630 | 0.79 | CA12 (0.40) | ZDHHC20ZDHHC2CA12CA1CA9 | |
| SCHEMBL28762352 | 0.76 | CA1 (0.38) | ZDHHC20ZDHHC2CA12CA1CA9 | |
| SCHEMBL8924940 | 0.75 | PDE4A (0.43) | ZDHHC20ZDHHC2CA12CA1CA9 | |
| SCHEMBL7749705 | 0.72 | CA12 (0.40) | ZDHHC20ZDHHC2CA12CA1CA9 | |
| SCHEMBL4081083 | 0.71 | ZDHHC20 (0.72) | ZDHHC20ZDHHC2CA12CA1CA9 | |
| SCHEMBL372601 | 0.71 | ZDHHC20 (0.72) | ZDHHC20ZDHHC2CA12CA1CA9 | |
| SCHEMBL137967 | 0.71 | ZDHHC20 (0.72) | ZDHHC20ZDHHC2CA12CA1CA9 | |
| SCHEMBL8618803 | 0.71 | CA12 (0.45) | ZDHHC20ZDHHC2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9320798-B2 | Lipid delivery formulations | DICERNA PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | LIPA, LIPC, CETP | ZDHHC20 50/4885ZDHHC2 61/4885CA12 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.